Nektar Therapeutics (NKTR) Begins Enrollment in SUMMIT-07 Ph-3 Study of NKTR-181
Tweet Send to a Friend
Nektar Therapeutics (NASDAQ: NKTR) today announced the enrollment of the first patient in SUMMIT-07, its initial Phase 3 study of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
